



COD 13923 1 x 50 mL
STORE AT 2-8°C
Reagents for measurement of ASO concentration Only for <i>in vitro</i> use in the clinical laboratory

**PRINCIPLE OF THE METHOD**

Serum anti-streptolysin O (ASO) causes agglutination of latex particles coated with streptolysin O. The agglutination of the latex particles is proportional to the streptolysin O concentration and can be measured by turbidimetry<sup>1</sup>.

**COMPOSITION**

- A. Reagent: 1 x 40 mL. Tris buffer 20 mmol/L, sodium chloride 150 mmol/L, sodium azide 0.95 g/L, pH 8.2.
- B. Reagent: 1 x 10 mL. Suspension of latex particles coated with streptolysin O, sodium azide 0.95 g/L.

**STORAGE**

Store at 2-8°C.  
Reagents are stable until the expiry date shown on the label when stored tightly closed and if contaminations are prevented during their use.  
Indications of deterioration:  
– Reagents: Absorbance of the blank over the limit indicated in "Assay Parameters".

**AUXILIARY REAGENTS**

S. ASO Standard: 1 x 1 mL (BioSystems Cod. 31119). Human serum. ASO concentration is given on the label. The concentration value is traceable to the Biological Reference Material WHO 97/662 (National Institute for Biological Standards and Control, NIBSC).  
*Human serum used in the preparation of the standard has been tested and found to be negative for the presence of antibodies anti-HIV and anti-HCV, as well as for HBs antigen. However, the standard should be handled cautiously as potentially infectious.*

Reconstitute with 1.00 mL of distilled water. Stable for 1 month at 2-8°C.

**REAGENT PREPARATION**

Working Reagent: Pour the contents of a Reagent B vial into a Reagent A bottle (Note 1). Mix thoroughly. Stable for 30 days at 2-8°C.  
Smaller Working Reagent volumes can be prepared by mixing: 1 mL of Reagent B + 4 mL of Reagent A. Shake the Reagent B vial before pipetting.  
Reagent open and kept in the refrigerated compartment of the analyzer is stable 1 month.

**SAMPLES**

Serum collected by standard procedures.  
Anti-streptolysin O in serum is stable for 7 days at 2-8°C.

**REFERENCE VALUES**

Serum<sup>2</sup>  
Adults: < 200 IU/mL  
Children: < 150 IU/mL

This range is given for orientation only; each laboratory should establish its own reference range.

**CALIBRATION**

It is recommended to do a reagent blank every day and a calibration at least every 1 month, after reagent lot change or as required by quality control procedures.

**ASSAY PARAMETERS**

		A25	A15	
GENERAL	Test name	ASO	ASO	
	Analysis mode	mono. end point	mono. end point	
	Sample type	SER	SER	
	Units	IU/mL	IU/mL	
	Reaction type	increasing	increasing	
	Turbidimetry test	yes	yes	
	Decimals	0	0	
	No. of replicates	1	1	
Test name in patient report	-	-		
PROCEDURE	Reading	bichromatic	bichromatic	
	Sample	3	3	
	Reagent 1	300	300	
	Reagent 2	-	-	
	Washing	1.2	1.2	
	Predilution factor	-	-	
	Postdilution factor	2	2	
	Filters	Main	535	535
		Reference	670	670
	Times	Reading 1	180 s	192 s
Reading 2		-	-	
Reagent 2		-	-	

CALIBRATION	Calibration type	specific	specific
	No. of calibrators	1	1
	Calibrator replicates	3	3
	Blank replicates	3	3
	Calibration curve	-	-
OPTIONS	Blank absorbance limit	0.900	0.900
	Kinetic blank limit	-	-
	Linearity limit	800	800

**QUALITY CONTROL**

It is recommended to use the Rheumatoid Control Serum level I (Cod. 31213) and II (Cod. 31214) to verify the performance of the measurement procedure.  
Each laboratory should establish its own internal Quality Control scheme and procedures for corrective action if controls do not recover within the acceptable tolerances.

**METROLOGICAL CHARACTERISTICS**

The following data were obtained using an A25 analyser. Results are similar with A15. Details on evaluation data are available on request.

- Detection limit: 14.3 IU/mL ASO
- Linearity limit: 800 IU/mL ASO. For higher values dilute sample 1/5 with distilled water and repeat measurement.
- Repeatability (within run):

Mean concentration	CV	n
205 IU/mL	4.5 %	20
349 IU/mL	3.4 %	20

- Reproducibility (run to run):

Mean concentration	CV	n
205 IU/mL	4.8 %	25
349 IU/mL	4.2 %	25

- Trueness: Results obtained with this procedure did not show systematic differences when compared with a reference procedure. Details of the comparison experiments are available on request.
- Zone effect: falsely low values are obtained when ASO is present in the sample at a concentration higher than 4000 IU/mL.
- Interferences: Hemoglobin (10 g/L), bilirubin (20 mg/dL), lipemia (triglycerides 10 g/L) and rheumatoid factors (2200 IU/mL) do not interfere. Other drugs and substances may interfere<sup>7</sup>.

**DIAGNOSTIC CHARACTERISTICS**

Anti-streptolysin O are the specific antibodies to streptolysin O, an extracellular enzyme produced by Lancefield group A, β-hemolytic streptococci (*Streptococcus pyogenes*). Antibodies against streptolysin O can be detected from one week to one month after the onset of a streptococcal infection. *Streptococcus pyogenes* causes a wide variety of upper respiratory infections such as acute pharyngitis. Other manifestations of *Streptococcus pyogenes* infection include glomerulonephritis, rheumatic fever, bacterial endocarditis and scarlet fever<sup>3-6</sup>.

Clinical diagnosis should not be made on the findings of a single test result, but should integrate both clinical and laboratory data.

**NOTES**

1. Shake the Reagent B vial gently before pouring its contents into the Reagent A bottle. It is advisable to wash the Reagent B vial with a small volume of the prepared mixture in order to completely rinse the vial and avoid any losses.

**BIBLIOGRAPHY**

1. Borque L, Rus A, Dubois H. Automated determination of streptolysin O antibodies by turbidimetric latex immunoassay method. *J Clin Immunoassay* 1992; 15: 182-6.
2. Klein GC, Baker CN, Jones WL. Upper limits of normal antistreptolysin O and antideoxyribonuclease B titers. *Appl Microbiol* 1971; 21: 758-60.
3. Bisno AL. Group A streptococcal infections and acute rheumatic fever. *N Engl J Med* 1991; 325: 783-93.
4. Stevens DL. Invasive group A streptococcal disease. *Clin Infect Dis* 1992; 14: 2-11.
5. Immunology and Serology in Laboratory Medicine, 2<sup>nd</sup> edition. Turgeon ML. Mosby, 1996.
6. Friedman and Young. Effects of disease on clinical laboratory tests, 4th ed. AACC Press, 2001.
7. Young DS. Effects of drugs on clinical laboratory tests, 5th ed. AACC Press, 2000.